ALLOGENE THERAPEUTICS INC. - COMMON STOCK

1.4400

04-April-25 16:45:00

15 minutes delayed

Stocks

+0.0600

+4.35%

Today's range

1.3200 - 1.4600

ISIN

N/A

Source

NASDAQ

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

08 Aug 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

07 Aug 2024 16:02:54 By Nasdaq GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

31 Jul 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

01 Jul 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

20 Jun 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

23 May 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

13 May 2024 16:47:42 By Nasdaq GlobeNewswire
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

13 May 2024 16:01:00 By Nasdaq GlobeNewswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

06 May 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

26 Apr 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Q2 Investor Conference Participation

09 Apr 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

14 Mar 2024 16:05:00 By Nasdaq GlobeNewswire
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

12 Mar 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

05 Mar 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

28 Feb 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

16 Feb 2024 08:30:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

16 Jan 2024 16:05:00 By Nasdaq GlobeNewswire
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

04 Jan 2024 16:15:00 By Nasdaq GlobeNewswire
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

04 Jan 2024 16:05:00 By Nasdaq GlobeNewswire
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.